iBio, Inc. Files 8-K Report

Ticker: IBIO · Form: 8-K · Filed: 2025-01-10T00:00:00.000Z

Sentiment: neutral

Topics: 8-K, disclosure, financials

TL;DR

iBio filed an 8-K on Jan 10, 2025, covering Reg FD, other events, and financials.

AI Summary

On January 10, 2025, iBio, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and other events, along with financial statements and exhibits. The company, formerly known as iBioPharma, Inc., is incorporated in Delaware and headquartered in Bryan, Texas.

Why It Matters

This 8-K filing provides updates on iBio, Inc.'s corporate activities and financial reporting, which are important for investors to monitor the company's status and compliance.

Risk Assessment

Risk Level: low — This filing is a routine 8-K report detailing corporate events and financial statements, not indicating any immediate significant risks.

Key Numbers

Key Players & Entities

FAQ

What specific events are being disclosed under Regulation FD?

The filing indicates a Regulation FD Disclosure but does not detail the specific information being disclosed in this excerpt.

What are the primary items covered in this 8-K filing?

This 8-K filing covers Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits.

When was iBio, Inc. formerly known as iBioPharma, Inc.?

The date of the name change from iBioPharma, Inc. to iBio, Inc. was August 6, 2008.

Where are iBio, Inc.'s principal executive offices located?

iBio, Inc.'s principal executive offices are located at 8800 HSC Parkway, Bryan, Texas 77807.

What is the fiscal year end for iBio, Inc.?

The fiscal year end for iBio, Inc. is June 30.

From the Filing

0001420720-25-000003.txt : 20250110 0001420720-25-000003.hdr.sgml : 20250110 20250110074707 ACCESSION NUMBER: 0001420720-25-000003 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 96 CONFORMED PERIOD OF REPORT: 20250110 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250110 DATE AS OF CHANGE: 20250110 FILER: COMPANY DATA: COMPANY CONFORMED NAME: iBio, Inc. CENTRAL INDEX KEY: 0001420720 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 262797813 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35023 FILM NUMBER: 25520461 BUSINESS ADDRESS: STREET 1: 600 MADISON AVENUE, SUITE 1601 CITY: NEW YORK STATE: NY ZIP: 10022-1737 BUSINESS PHONE: 302 355-0650 MAIL ADDRESS: STREET 1: 600 MADISON AVENUE, SUITE 1601 CITY: NEW YORK STATE: NY ZIP: 10022-1737 FORMER COMPANY: FORMER CONFORMED NAME: iBioPharma, Inc. DATE OF NAME CHANGE: 20080806 FORMER COMPANY: FORMER CONFORMED NAME: InB:Biotechnologies, Inc. DATE OF NAME CHANGE: 20071210 8-K 1 ibio-20250110x8k.htm 8-K iBio, Inc._January 10, 2025 0001420720 false 0001420720 2025-01-10 2025-01-10 ​ ​ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM  8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 10, 2025 iBio, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) ​ ​ 001-35023 26-2797813 (Commission File Number) (IRS Employer Identification No.) ​ 8800 HSC Parkway Bryan , Texas 77807 (Address of principal executive offices and zip code) ( 979 ) 446-0027 (Registrant’s telephone number including area code) N/A (Former Name and Former Address) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions: ☐       Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐       Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12) ☐       Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐       Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: ​ ​ ​ Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value per share IBIO NYSE American ​ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company   ☐ If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨ ​ ​ ​ Item 7.01.       Regulation FD Disclosure.   iBio, Inc. (the “Company”) has updated its corporate presentation. A copy of the updated corporate presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K. ​ The information in this Item 7.01 and in the corporate presentation attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Secur

View on Read The Filing